1. 1 J Sterne, M May, and D Costagliola et al. Estimating the optimum CD4 threshold for starting HAART antiretroviral-naive HIV-infected individuals. 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado [Abstract 525].
2. 2 B Marin, R Thiebaut, and V Rondeau et al. Association between CD4 and HIV RNA with non AIDS-related causes of death in the era of combination antiretroviral therapy (cART). Third International AIDS Society Conference of HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia [Abstract WEPEB019].
3. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
4. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era
5. Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV